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1 Sepsis and the critically ill patient
Sepsis remains common in critically ill patients. The prevalence 
of systemic inflammatory response syndrome (SIRS) is 
estimated to range from 20% to 60%, with approximately 
40% of patients with sepsis developing septic shock.5 Severe 
sepsis and septic shock have high mortality rates and are the 
leading cause of death in Intensive Care Units.6 
1.1 Metabolic Response to sepsis and critical illness
The metabolic response to stress is part of an adaptive 
response to survive critical illness and restore homeostasis 
as rapidly as possible. Sir David Cuthbertson described 
several phases of metabolic response over time, including 
the ‘ebb’ and ‘flow’ phases. More recently, the chronic or post-
injury phase, frequently encountered in the Intensive Care 
Unit (ICU) has been added.7 The ebb phase occurs several 
hours after the injury and lasts for 12–24 hours, consists of 
reductions in cardiac output, oxygen consumption (VO2), 
the basal metabolic rate, and glucose tolerance. The flow 
phase lasts for 3–8 days, depending on injury severity. It is 
characterised by increases in cardiac output, respiratory 
rate, VO2, hyperglycaemia, skeletal muscle catabolism, and 
a negative nitrogen balance.8 The post injury phase lasts for 
some weeks, as protein and fat stores are restored and weight 
regained.9 
The central nervous system partially regulates the 
inflammatory component via pro- and anti-inflammatory 
cytokines and other inflammatory mediators. These cytokines 
are signalling peptides produced by inflammatory cells, and 
released in response to injury.10 
The pro-inflammatory cytokines released, namely, tumour 
necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-6 and 
IL-8, impair some of the body’s physiological functions 
and play pivotal roles in the metabolic changes associated 
with sepsis. They initiate the acute phase response, recruit 
reticuloendothelial cells (lymphocytes, macrophages 
and monocytes), promote wound repair and induce the 
production of other cytokines.7,9 To balance and control 
inflammation, coexistent anti-inflammatory cytokines, 
IL-10 and IL-13, are produced.10 The inflammatory response is 
initiated by activation of the innate immune system by pro-
inflammatory stimuli such as damage-associated molecular 
patterns (DAMPS) and pathogen associated molecular 
patterns (PAMPS).11 In addition to typical clinical signs of 
sepsis, like fever and lethargy, these cytokines also trigger 
anorexia and induce weight loss, proteolysis and lipolysis.7 
Levels of TNF-α and IL-6 have consistently been shown to 
correlate with the mortality and poor outcome following 
severe injury and sepsis. Both TNF-α and IL-10 levels are 
associated with mortality.10   
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This literature review focuses on the administration of different lipid emulsions, in particular omega-3 PUFA via the parenteral 
nutrition route, in critically ill adult patients. The clinical consequences associated with critical illness as well as the administration 
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Recently, the term persistent inflammation, 
immunosuppression, and catabolism syndrome (PICS) is 
used to describe the observed phenotype of chronic multi 
organ failure (MOF). Patients with PICS experience prolonged 
low-grade inflammation and catabolism with resultant loss 
of lean body mass (LBM). The PICS paradigm is as follows: 
following a major inflammatory insult (sepsis, trauma, 
burns, acute pancreatitis, etc.) there are simultaneous 
inflammatory (SIRS) and anti-inflammatory – compensatory 
anti-inflammatory response syndrome (CARS) – responses. 
In some cases, the SIRS becomes overwhelming, leading to 
early MOF and death.12,13 
Modern ICU care focusses on early recognition of shock 
and treatment. If patients do not die of early MOF, there 
are two possible pathways. Either their immunity recovers 
rapidly, immune homeostasis is achieved and they recover, 
or immunologic dysfunction persists and they enter chronic 
critical illness (CCI), defined as > 14 days in the ICU with 
organ dysfunction. These patients with CCI experience 
ongoing immunosuppression and inflammation associated 
with a persistent acute phase response (e.g. high C reactive 
protein) with ongoing protein catabolism. Despite aggressive 
nutrition intervention, there is a remarkable loss of LBM 
associated with a proportional decrease in functional status 
and poor wound healing.12,13
1.2 Nutritional consequences and management of 
critically ill patients
The metabolic response to stress has several clinical 
consequences from changes in metabolic rate to use of 
macronutrients as energy sources, stress hyperglycaemia, 
muscle wasting, changes in body composition and 
behavioural changes.7
Current management aims to control infection, achieve 
haemodynamic stabilisation and modulate the immune 
response to provide organ and metabolic support, by treating 
the source and providing adequate oxygen delivery, ensuring 
glucose control and initiating nutrition therapy (NT).14
NT is important in all critically ill patients and the goals focus 
on attenuating the metabolic response to stress, preventing 
oxidative cellular injury, and favourably modulating the 
immune response.15 This includes providing adequate 
nutrition, preventing nutritional deficiencies, preserving lean 
body mass, maintaining glucose control, avoiding metabolic 
complications, decreasing infectious complications and 
improving clinical outcomes.16 The enteral route is preferable 
and should be commenced once initial resuscitation and the 
patient is haemodynamically stable.17 Where enteral nutrition 
(EN) is impossible or not tolerated, parenteral nutrition (either 
as total or supplementary) may safely be administered.18
Many critically ill patients develop muscle wasting and 
weakness, with an adverse outcome. This is due to the 
hypercatabolism of critical illness as well as anorexia, 
gastrointestinal dysfunction and resultant decreased 
nutritional intake that accompanies severe illness.19 Recent 
research indicates that critically ill or major surgical patients 
can lose as much as a kilogram of lean body mass (LBM) a 
day, during the first week of ICU stay. Patients may regain 
weight post-ICU, but much of the weight gain is fat mass, not 
functional lean muscle mass.20
NT in general will not be discussed in the literature review. 
1.3 Parenteral Nutrition (PN)
PN is the intravenous administration of macronutrients 
and micronutrients.21 Differences in timing of initiating PN 
according to various guidelines are particularly due to the 
differences between the target populations, the levels of 
evidence considered, and the different types of PN products 
available.22 All guidelines agree that in patients with or at high 
risk of malnutrition, PN should be initiated early following 
ICU admission if EN is impossible. 
Despite numerous randomised control trials, observational 
studies, systematic reviews and consensus guidelines on 
NT in critical illness, many issues remain controversial, 
including the ideal method of assessing energy and protein 
requirements as well as optimal nutritional targets.22
1.4 Lipid 
Intravenous lipid emulsions (LE) provide a source of 
essential fatty acids (EFA) and serve as a complement to 
carbohydrates by providing a dense source of Non Protein 
Energy (NPE). Addition of lipid to PN allows sufficient 
calories to be administered without excess fluid. LE also 
have a low osmolarity, thus reducing the overall osmolarity 
of the solution enabling some solutions to be administered 
peripherally (≤  900  mOsm/L) or centrally.28 Table 1 for 
published guidelines for lipid intake in critically ill patients 
requiring PN.
Fatty acids are classified according to their structure, carbon 
chain length (short, medium or long), degree of saturation 
(number of double bonds), and the location of double 
bonds (counted from the methyl carbon of the hydrocarbon 
chain).3,28 They play key roles in determining the structural 
integrity and fluidity of cell membranes and can give rise 
to several important bioactive mediators. They can also 
regulate the expression of a variety of genes and modulate 
cell signalling pathways, such as those involved in apoptosis, 
inflammation and cell-mediated immune responses.28,29 
Changing the FA composition of cells involved in the 
inflammatory response influences their functions: the anti-
inflammatory effects of marine ω-3 PUFA suggest that they 
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may be useful as therapeutic agents in disorders with an 
inflammatory component.30
The metabolites of ω-3 PUFA, primarily from Eicosapentaenoic 
acid (EPA) and Docosahexaenoic acid (DHA), compete 
with arachidonic acid (AA) for use of the same enzymes, 
cyclooxygenase and lipoxygenase. As a result, a higher 
intake of ω-3 PUFA leads to both an increase in anti-
inflammatory mediators (namely prostaglandins of the 
3 series and leukotrienes of the 5 series) and a decrease in 
pro-inflammatory mediators31,32 (See Figure 1).
Difference between IVLE
The first LE developed in 1961 that met the criteria for safe 
use as part of PN in the clinical arena was 100% soybean oil 
(SO). This was a landmark that triggered the launch of lipid-
based PN in Europe and prevented the complications of 
high-dose dextrose infusions that were seen with the use of 
lipid-free PN in the USA.21 
Soybean Oil
SO lipid emulsions still remain the most widely used in 
many countries because of its proven record of safety and 
tolerability.3,4 SO contains high concentrations of PUFA with 
a ratio of Linoleic acid (LA) to Alpha-Linolenic acid (ALA) of 
approximately 7:1. LA is metabolised into Arachidonic acid 
(AA). The eicosanoids generated from AA are prostaglandin 
E2 (PGE2), thromboxane A2 (TXA2) and leukotrienes including 
LTB4, which are pro-inflammatory (Figure 1). The SO is naturally 
rich in phytosterols and has high levels of γ-tocopherol but 
low amounts of α-tocopherol (bioactive form of vitamin E). 
The phytosterols present in SO are plant sterols thought to 
contribute to the development of intestinal failure–associated 
liver disease (IFALD). The role of phytosterols in hepatocyte 
damage has been demonstrated by their antagonising 
effect on the farsenoid X nuclear receptor, which is critical 
in regulating the level of intrahepatic bile acids. In addition, 
the incorporation of phytosterols in erythrocyte membranes 
accelerates breakdown of these cells and increases the 
bilirubin load to the liver.29
Emulsions with a high content of ω-6 PUFA have been linked 
to immunosuppression.34,35 One study evaluated the effect 
of lipid intake on the postoperative stress response and cell-
mediated immune function of patients subjected to gastric 
or colorectal surgery. Higher postoperative concentrations of 
IL-6 and C-reactive protein were seen in patients receiving a 
SO LE compared with those receiving lipid free PN.36 This is 
why many centres do not administer 100% SO LE to critically 
ill patients.29 The emergence of this evidence has led to the 
development of the next-generation LE based on various oil 
sources.3,4
Coconut Oil (MCTs)
Second generation LE consisted of the addition of MCT 
to SO. It contains a 50/50 mixture, thus reducing the ω-6 
PUFA content by 50%. MCTs are SFA 6-12 carbons long and 
include caprylic and capric acids. They are easily metabolised, 
require little carnitine for mitochondrial entry and lack pro-
inflammatory properties, both characteristics unique to this 
fat source. MCTs are also hydrolysed and eliminated from the 
central circulation more quickly than LCTs, which makes them 
a preferred caloric source. Additionally, MCTs are resistant to 
peroxidation and do not accumulate in the liver. However, 
MCT oils are devoid of EFAs and thus cannot be used as a sole 
source of fat.2,29
Olive Oil
Olive oil (OO) is rich in ω-9 FA, (oleic acid) a type of MUFA not 
considered essential. OO-based emulsions were introduced 
in Europe in the 1990s and are classified as third generation 
IVLE. The relatively small amount of LA explains why this oil 
source requires blending with an oil containing EFA, like SO. 
OO has a lower content of phytosterol than pure SO and is 
rich in MUFAs, which are immune-neutral and are more 
resistant to oxidative stress injuries from free radicals.29,32 
Fish Oil
Fish Oil (FO)based LE are the most recent development as 
an alternative to SO and are known as the fourth generation 
IVLE. They have been available in Europe and Asia for the 
past 10 years as a supplement to the conventional SO-based 
LE (Omegaven). More recently, FO has been included in a 
combination emulsion consisting of soybean (30%), MCT 
(30%), olive (25%) and fish oil (15%) (SMOFlipid). Mixing four 
different oils optimises the fatty acid profile and complies 
with current recommendations of ω-6:ω-3 PUFA ratio of 
2.5:1.37
Due to the high concentrations of EPA and DHA, FO is 
thought to have anti-inflammatory potential by interfering 
with the AA pathway and producing the anti-inflammatory 
eicosanoids prostaglandins E3 (PGE3), thromboxanes A3 (TXA3) 
and leukotrienes B5 (LTB5) as well as resolvins, protectins and 
maresins. FO is also rich in the antioxidant α-tocopherol, 
which is added to prevent the oxidation of its FA.32,38 
Despite sharing several common properties, the oil sources 
used and the percentages of different oils dictate the key 
differences between intravenous lipid emulsions (IVLE). 
Their differences account for their additional benefits or 
detriments, especially when used for prolonged periods 
(Table 2 for the analysis of LE). Typical IVLE are manufactured 
with 1 of 4 types of oil; soybean, coconut, olive or fish. Each 
has unique inflammatory properties and may even confer 
different pharmaceutical and therapeutic benefits.29
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Omega 6: omega 3 PUFA ratio
In an experimental immunocompetence model, Grimm et al. 
demonstrated that IVLE show varying immunomodulatory 
effects dependent on the ω-6:ω-3 PUFA ratio. The optimum 
immune response was maintained by infusion of a lipid 
emulsion with a ω-6:ω-3 PUFA ratio of 2.1:1.39 According to 
recommendations, new lipid emulsions should be composed 
of a reduced ω-6 PUFA, especially LA, counterbalanced by 
MCT,  MUFA and long-chain ω-3 PUFA. Based on experimental 
and clinical studies, the most favourable ω-6:ω-3 PUFA ratio is 
proposed to range between 2:1 and 4:1.4,39-41
Various professional organisations have developed consensus 
guidelines for prescribing different types of lipids in PN (Table 
1). These guidelines vary in their recommendations according 
to the types of lipids available and registered in the various 
countries. Until recently, FO containing lipid emulsions were 
not available in the US, unless under special concession. 
However, SO/MCT/OO/FO LE (SMOFlipid) was registered by 
the FDA in 2016.
1.4.1 Lipid Emulsions: Overview of Clinical Benefit
Discrepancies occur between the different clinical and 
experimental study results partly due to the lack of 
standardised criteria and because of the different PN 
formulations. Moreover, the clinical relevance of animal 
models has been largely criticised, as they invariably fail to 
reproduce the complexity of human illness.1 Human studies 
conducted in adult patient populations, comparing FO LE to 
alternatives, are discussed further in this review.
1.4.1.1 Critical Illness
The biological effects associated with LE are likely to benefit a 
majority of patients under metabolic stress receiving PN. 
Griffin highlighted the fact that reversing the negative 
nitrogen balance in septic patients would probably be 
impossible to achieve without therapeutic manipulation of 
cytokine or cyclooxygenase inhibitors.45
Numerous studies in ICU patients indicate the clinical value 
of ω-3 PUFA in critically ill patients (Table 3). Mayer et al. (46,47) 
showed that ω-3 PUFA infusion for 5 days increased free ω-3 
PUFA and reversed the ω-6:ω-3 PUFA ratio within 24 to 48 
hours to an ω-3 over ω-6 predominance. Moreover, ω-3 PUFA 
were incorporated into mononuclear leukocyte membranes, 
with significantly increased EPA and DHA content and 
significantly increased (EPA+DHA)/AA ratio. Serum cytokine 
levels (TNF-α, IL-1β, IL-6 & IL-8) decreased by 30% in patients 
treated with FO, whereas it doubled in those treated by LCTs 
(ω-6 PUFA).
Heller et al. demonstrated that IV FO administered for 
≥  3 days improved survival and reduced infection rates, 
antibiotic requirements and length of stay (LOS) at doses of 
0.15 – 0.2g FO/kg/day.48
A randomised study conducted by Khor et al. comparing IV FO 
vs saline in 28 critically ill patients with severe sepsis showed 
a significant APACHE II score and serum PCT reduction on day 
3, 5 and 7 in the FO group. However, serum TNF-α level, LOS of 
ICU and hospital stay was not significantly different.6
Barbosa et al. studied the effects of FO LE on 25 septic patients 
for 5 days. The FO group had an increase in plasma EPA level. 
The plasma IL-6 concentration decreased more, and IL-10 
significantly less, in the FO group. There was no difference in 
days of mechanical ventilation (MV), ICU LOS and mortality. 
The FO group tended to have a shorter hospital LOS which 
became significant when only surviving patients were 
included.49 Another study conducted in 20 patients with SIRS 
and 20 patients with sepsis showed an increase in TNF-α and 
IL-6 values on day 7, whereas IL-1 values were significantly 
higher on days 3, 7 and 10 in the MCT/LCT group. Conversely, 
IL-10 values on days 3 and 7 were significantly higher in the 
FO group.50 
Grecu et al. compared LCT + FO vs LCT in 54 patients with 
abdominal sepsis for 5 days and showed significantly lower 
reoperation rates, ICU and hospital LOS. The CRP levels were 
also lower in the FO group on day 5, but they found no 
difference in mortality.51 
However, in a study conducted in 166 medical critically 
ill patients, comparing MCT/LCT LE to MCT/LCT plus FO 
supplementation for more than 6 days, there was no 
significant difference in terms of IL-6 levels and clinical 
outcomes (infections, duration of MV, ICU LOS and 28 day 
mortality).52 
Another study conducted by Hall et al. in 60 critically ill 
patients with sepsis studied the effects of parenteral ω-3 
PUFA (0.2g FO/kg/day) administered as an independent drug 
and standard medical care vs standard medical care. The FO 
supplemented group had a significant decrease in new organ 
dysfunction (assessed by delta-SOFA and maximum SOFA) 
and maximum CRP. There was no significant reduction in LOS 
between cohorts and no associated reduction in 28-day or 
inpatient mortality; however, in the less severe sepsis group 
there was a statistically significant reduction in mortality.53
Edmunds et al. used a secondary analysis from an 
International Nutrition database and compared the effects 
of different IV LE on clinical outcomes in critically ill patients. 
They showed that compared to lipid-free PN, patients who 
received FO have faster time to ICU discharge. Compared to 
LCT, patients who received OO or FO had a shorter time to 
termination of MV alive and a shorter time to ICU discharge.54
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All the above studies had very small numbers so their 
significance is uncertain. The dose of FO as well as the 
duration also differed.
Four meta-analyses have studied different LE in critically 
ill patients.55-58 They found no difference in mortality, but a 
significant reduction in hospital LOS with IV FO LE. However, 
two of these meta-analyses showed significant reduction in 
infection rate in the group receiving FO supplemented PN.55,57 
Also, Pradelli et al. showed reduced inflammation markers in 
the FO group, especially IL-6, and a shift towards LTB5 series 
production.57 He conducted a cost effectiveness analysis on 
PN regimens containing omega-3 PUFA in ICU patients. The 
reduction in infection rates and overall LOS translated to a 
cost saving of between €3972 and €4897 per ICU patient.59 
A recent review published found insufficient high-quality 
data investigating inflammatory and immune markers as well 
as clinical outcomes to determine the true effect of PN with 
FO containing LE compared to other IVLE.60
1.4.1.2 Lipid Emulsions in ARDS
The acute phase of ARDS can be a component of sepsis 
and septic shock with comparable pathogenesis and is 
characterised by an excessive inflammatory response with 
the release of pro-inflammatory cytokines and eicosanoids. 
The alveolar-capillary barrier is altered, resulting in vascular 
permeability and neutrophil leakage into the alveolar and 
interstitial space.1 The main clinical features of ARDS include 
rapid onset of dyspnoea, severe defects in gas exchange and 
diffuse pulmonary infiltrates on x-rays.62 
The role of nutrition in the management of ARDS has 
traditionally been supportive. Recent research demonstrated 
the potential of certain dietary lipids (e.g., fish oil, borage oil) 
to modulate pulmonary inflammation, thereby improving 
lung compliance and oxygenation, and reducing time on 
ventilator.62
While LE appear to be safe in patients with normal lung 
function or chronic obstructive pulmonary disease, soybean-
based emulsions have been shown to induce several 
modifications in gas exchange and pulmonary inflammation 
in patients with acute respiratory failure.63,64 The deleterious 
effects appear to be predominantly due to their high 
proportion of LA and to excessive or rapid LCT infusion.65 
This reduces  PaO2/FiO2 ratio, pulmonary blood pressure and 
vascular resistances, through an imbalance in production of 
vasodilating and vasoconstricting eicosanoids.64,66 
The effects of a fish oil containing LE as part of PN was studied 
in 25 septic patients, showing improved gas exchange. At Day 
6, the PaO2/FiO2 ratio was significantly higher in the fish oil 
group. However, days on MV did not differ.49 Another study67 
using the same LE in patients with ARDS showed significant 
short term changes in anti-inflammatory eicosanoid values. 
However, in an earlier study by the same group in ARDS 
patients, they could not demonstrate significant changes in 
haemodynamics and gas exchange.68
Similar results have been shown in studies using ω-3 PUFA as 
part of enteral nutrition69-72, but as this falls beyond the scope 
of this review it will not be discussed. 
1.4.1.3 Lipid emulsions and surgical patients
There are numerous clinical studies (Table 4) on the efficacy 
and safety of LE in surgical patients. LCTs were the first LE 
used in post-surgical patients and were found to increase 
proinflammatory cytokines and decrease T-cell proliferation 
in stressed patients, while having no effect in unstressed 
patients.73
There is data using fish oil containing LE in surgical patients 
showing a good safety profile, generation of ω-3 PUFA derived 
lipid mediators and a reduced length of stay. The use of fish 
oils in these patients has shown improved plasma levels of 
α-tocopherol and better liver tolerance.74-81 Mayer concluded, 
based on a review of the available evidence, that inclusion of 
ω-3 PUFA in PN improves immunologic parameters and LOS 
in surgical patients.82
A meta-analysis conducted by Chen et al.83 reviewed the 
safety and efficacy of fish oil enriched PN in postoperative 
patients undergoing major abdominal surgery. He showed 
that fish oil-enriched PN had a positive effect on length of 
hospital stay (-2.98 days), length of ICU stay (-1.8 days) and 
reduction in postoperative infection rate by 44%. Levels of 
aspartate aminotransferase and alanine aminotransferase 
reduced and plasma α-tocopherol increased. These results 
were also confirmed in the meta-analysis by Wei et al.84 Tian 
et al. showed similar results in reduction in liver enzymes, 
triglycerides and CRP in the FO group, but no difference in 
hospital LOS.85
Recently, a more extensive meta-analysis analysed the 
clinical efficacy and safety of ω-3 PUFA-enriched parenteral 
LE in elective surgical and ICU patients. The results showed 
that ω-3 PUFA-enriched emulsions were associated with a 
clinically significant reduction in infection rate and length 
of stay, both in ICU (-1.92 days) and in hospital overall 
(-3.29 days). Other beneficial effects shown included reduced 
markers of inflammation, improved lung gas exchange, liver 
function, antioxidant status and fatty acid composition of 
plasma phospholipids, and a trend towards less impairment 
of kidney function.57 
1.4.1.4 Lipid Emulsions and Parenteral Nutrition 
Associated Liver Disease (PNALD)
The administration of PN has been associated with liver 
changes such as steatosis, steatohepatitis, fibrosis, cirrhosis, 
and biliary changes such as cholestasis, cholelithiasis and 
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cholecystitis. These changes may occur in 25–100% of adult 
patients who receive PN. Liver involvement may progress to 
cirrhosis, possibly requiring liver and bowel transplant.100
Diagnosis depends on bilirubin and liver enzyme levels. 
The correlation between changes in laboratory tests and 
histopathological findings in liver biopsies is low.101
There are various factors associated with liver changes 
associated with PN; namely, duration on PN, overfeeding 
especially with calories, lipid load, high phytosterol intake 
and low α-tocopherol intake. Table 2 for phytosterol and 
α-tocopherol content of different LE.
The effects of FO LE compared to other LE on liver dysfunction, 
have been studied in surgical patients. FO LE showed 
improvement in liver enzymes and plasma α-tocopherol 
levels.74,75,78,80,86,90,93 Some studies showed no difference liver 
function test with FO LE.88,92,96
Sungurtekin et al. demonstrated an increase in liver steatosis 
on day 7 and 10 in patients with sepsis and SIRS on PN without 
FO.50 Recently, a retrospective study was conducted in adult 
patients receiving FO supplementation in PN. GGT, ALP and 
ALT decreased with FO PN supplementation. The decrease 
was greater when the doses of FO were higher (0.71  g 
FO/kg – 5.28 g FO/kg).102
Two studies conducted in patients undergoing liver 
transplantation, compared PN with and without FO. 
A significant reduction in ALT and Prothrombin Time was seen 
in the FO group with a significant decrease in post-transplant 
hospital stay.103,104 
Reduction in liver enzymes and improved antioxidant status 
was also shown in four meta-analyses.57,83,85,105 The dosage of 
FO that showed benefit was 0.1 – 0.15 g/kg/day57 and 0.07 – 
0.225 g/kg/day83.
Klek et al.106 performed a study to evaluate the safety and 
efficacy of a soybean/MCT/olive/fish oil LE vs a soybean oil 
emulsion in intestinal failure patients on long-term parenteral 
nutrition. After four weeks on PN, the patients receiving the 
fish oil containing LE had significantly lower liver enzymes, 
increased serum α-tocopherol and a positive change in their 
fatty acid profile. 
1.4.2 Complications associated with IV Lipid Emulsions
The IVLE component in PN can cause several metabolic and 
physiological adverse effects (AEs).
a.  Hypertriglyceridaemia
Hypertriglyceridaemia is one of the most common AEs 
and can predispose patients to elevations in liver enzymes, 
haemolysis and respiratory distress.29 The tolerance of lipids 
is monitored by measuring plasma triglyceride (TG) levels. An 
increase in plasma triglyceride levels indicates that the rate of 
lipid infusion exceeds the rate of hydrolysis. Lipoprotein lipase 
(LPL) is the enzyme responsible for hydrolysing triglycerides 
into two free fatty acids. Sepsis and steroids are two examples 
of factors which decrease LPL activity.107 
LCT and LCT/MCT LE have been shown to increase plasma 
triglyceride levels, whereas FO containing LE have shown 
a significant reduction in plasma triglyceride levels in both 
surgical and septic patients or the ability to maintain the 
levels within normal ranges74,76,78,86-88 (Tables 3 and 4).
A meta-analysis conducted by Chen et al. on the safety 
and efficacy of FO enriched PN in postoperative patients 
undergoing major surgery found no significant difference 
in plasma TG levels compared to PN without FO.83 However, 
the meta-analysis conducted by Tian et al. found significant 
differences between LCT/MCT/OO/FO vs LCT and vs OO/LCT 
suggesting beneficial effect of FO containing LE in surgical 
patients.85
In general, IVLE should not be infused in patients with plasma 
triglycerides (TGs) > 3-4 mmol/l, and  those with high basal 
(> 2-3 mmol/l) TG concentrations should be closely monitored 
to avoid complications.4 The SA National Parenteral Nutrition 
Practice Guidelines for Adults recommend that in the case of 
hypertriglyceridemia, the amount of lipid infused should be 
reduced and/or the type of fat should be changed.27
b. Fat overload syndrome
Fat overload syndrome is another complication associated 
with rapid infusion and/or high doses of IVLE therapy. It 
presents with headaches, jaundice, hepatosplenomegaly, 
respiratory distress and spontaneous haemorrhage. Other 
symptoms of fat overload include anaemia, leukopenia, 
thrombocytopenia, low fibrinogen levels, and depressed 
levels of coagulation factor V. These symptoms can be 
reversed by stopping the IVLE infusion or prevented by 
administering LE as part of an all-in-one PN solution, 
infused at a controlled rate over 24 hours.29 Guidelines from 
ESPEN recommend that IVLE be administered at a rate of 
0.7 – 1.5 g/kg over 12 – 24 hours.4 FO LE seem to reduce the 
risk of lipid overload by accelerating TG clearance more than 
SO LE. Despite being cleared more efficiently, FO LE undergo 
less catabolism than SO LE. The mechanism involved in the 
hydrolysis of FO LE and SO LE is very different. It appears that 
FO does not reduce the production of TG but rather enhances 
the clearance of emulsion particles and may not predispose 
patients to the complications associated with rapid infusion 
of SO LE.29
c. Hepatic abnormalities
The hepatic abnormalities induced by PN administration 
manifest differently depending on whether they occur in 
adults or children. In adults, fat accumulation more often 
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leads to benign, asymptomatic steatosis, with mild to 
moderate transaminitis (ALT > 42 IU/L and AST > 40 IU/L)100 
and hyperbilirubinaemia (>  34 µmol/L).42 Risk factors for 
the development of PNALD have been addressed briefly 
previously.
d. Essential Fatty Acid Deficiency (EFAD)
Linoleic acid and alpha linolenic acid are the two essential FA 
that cannot be synthesised by the human body. The typical 
ICU patient requires 9-12 g/day LA and 1-3 g/day ALA. Their 
importance is emphasised by their further metabolism to AA, 
and EPA and DHA.25 Low essential FA intake eventually leads 
to EFAD, which is associated with water losses from the skin 
due to increased permeability, susceptibility to infections, 
lowered resistance to irradiation injury and impaired wound 
healing, hematologic disturbances, fat infiltration of the 
liver, impaired chylomicron synthesis, and heightened fat 
absorption. EFAD is a potential effect of FO LE therapy as 
sole FA source or a reduction of SO LE.4 At least 2–4% of total 
calories should be administered as linoleic acid to prevent 
EFA deficiency101 or essential FA should be provided at 
7-10 g/day, equating to 14–20 g LCT or 30–40 g/day LCT from 
OO/LCT mix.27
e. Pulmonary Complications
Parenteral SO LE have been shown to induce inflammation 
of pulmonary vessels, leading to pulmonary hypertension, 
phagocyte activation, and the formation of granulomas.63,64 
The accumulation of lipid droplets in the microcirculation can 
compromise pulmonary gas exchange, by actions of lipid-
derived mediators such as eicosanoids and peroxides or by 
the diminished availability of the vascular relaxant NO.4,66
The administration of FO LE has been shown to improve gas 
exchange and reduce pro-inflammatory eicosanoids.49,57
f. Oxidative Stress
Unsaturated FA, such as LA may lead to oxidative stress 
because they can undergo lipid peroxidation that involves 
incorporation of an oxygen molecule into the FA when 
breaking down the double bonds. This produces lipid 
peroxides, which are unstable molecules and are converted 
to volatile metabolites that can trigger chain reactions, 
resulting in inactivation of enzymes, proteins and other 
elements necessary for viability of cells.32
Vitamin E, a powerful antioxidant, can protect against 
peroxidation. Storage conditions, such as light exposure and 
temperature can also influence peroxidation. MCTs consist 
of saturated FA, and oleic acid in olive oil is a MUFA, both of 
these FA types are resistant to peroxidation.4
g. Coagulation Complications
The effect of LE on coagulation have not been extensively 
assessed.28 
Currently there is no evidence of adverse effects of FO LE 
based on an increased bleeding risk due to their antiplatelet 
effects.57 Heller et Al.94 investigated the issue of potential 
coagulation disturbances associated with postoperative 
parenteral FO administration after major abdominal surgery. 
Their findings suggest that the infusion of fish oil in doses 
up to 0.2 g/kg BW per day is safe regarding coagulation and 
platelet function. Even with administration for up to four 
weeks, FO containing PN did not alter the haematological 
parameters and the INR remained unchanged.106
h. Immune Function and Infections
LE can influence immune systems, as addressed previously; 
there are concerns that pure SO LE might impair clinical 
outcomes due to their potential to promote inflammation 
and inhibit immune responses, especially in situations with 
an overproduction of proinflammatory mediators such as 
trauma or sepsis (Tables 3 and 4). Early clinical trials alluded to 
this effect; however, the clinical evidence for this is not strong. 
Methodologically flawed studies using hypercaloric feeding 
regimens and extrapolations from highly experimental 
approaches play an important role in this debate.4
Current recommendations are that new lipid emulsions 
should be composed of a reduced ω-6 PUFA, especially 
linoleic acid, counterbalanced by MCT, MUFA and long-chain 
ω-3 PUFA.4,39-41
2 Monitoring
Close monitoring of all patients receiving PN daily should 
include assessment of clinical, laboratory (Table 5) and 
nutritional indices. This guarantees that the nutrition 
prescription is appropriate and adequate and that the risks 
of complications are minimised.21,108 Clinical evaluation 
includes monitoring vital signs, fluid balance, stool output 
and a physical examination (abdomen and line site). The PN 
bag should be checked for leakage, cracking or separation 
of content, infusion rate and nutritional prescription, 
and nutritional intake should be monitored. Readiness 
to introduce enteral or oral nutrition should be assessed 
daily.21,27,108,109
Monitoring patients on PN is necessary to determine 
efficacy of specialised nutrition therapy, detect and prevent 
complications, evaluate changes in clinical condition and 
document clinical outcomes.21,108.
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3 Conclusion
The use of omega-3 PUFA in critically ill adult patients 
remains controversial as there are some conflicting results 
from previous reviews and meta-analysis. The need for 
further research remains a priority, on account of study 
heterogeneity, few significant differences in outcomes, rates 
of infection and sepsis, as well as differences in the timing 
and dose of FO administration.
Table 1: Published guidelines for lipid intake in critically ill patients requiring PN
Society Year Lipids (g)
ACCP (23) 1997 No recommendations
CCCPG (24) 2015 Consider IV lipids that reduce the load of omega-6 PUFA fatty acids/soybean oil emulsions.
Insufficient data to make a recommendation on the type of lipids to be used that reduce the omega-6 PUFA fatty acid/
soybean oil load 
ESPEN (25, 
26)
2009
2017
Lipid emulsions should be an integral part of PN for energy and to ensure EFA provision in long-term ICU patients
IVLE (LCT, MCT or mixed emulsions) can be administered safely at a rate of 0.7 g/kg up to 1.5 g/kg over 12 to 24 hours
Addition of EPA and DHA to lipid emulsions has demonstrable effects on cell membranes and inflammatory processes. 
Fish-oil enriched lipid emulsions probably decrease length of stay in critically ill patients.
Surgery:
Consider Postoperative PN including omega-3 PUFA.
ASPEN (17) 2016 Withhold or limit SO based IVLE during the first week following initiation of PN in the critically ill patient to a maximum 
of 100g/week.
Alternative IVLE may provide outcome benefit over soy-based IVLE; however recommendation cannot be made at this 
time due to lack of availability of these products in US.
SA National 
DOH (27)
2016 0.7-1.5 g/kg/day
Essential FA: 7-10 g/day, equating to 14-20 g LCT or 30-40 g LCT from OO/LCT mix.
IV FO administration: 0.1-0.2 g/kg/day
FO containing LE have been shown to be anti-inflammatory and contain less hepatotoxic phytosterols
Abbreviations: ACCP: American College of Chest Physicians; CCCPG: Canadian Critical Care Practice Guidelines; ESPEN: European Society for Clinical Nutrition and Metabolism; ASPEN: American 
Society of Parenteral and Enteral Nutrition; SA National DOH: South African National Department of Health; ICU: Intensive Care unit; IVLE: Intravenous Lipid Emulsions; FO: Fish oil; LCT: Long 
chain triglycerides; MCT: Medium chain triglycerides; OO: Olive oil; FA: Fatty acids
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Figure 1: Metabolism of Omega-6 and Omega-3 polyunsaturated fatty acids (adapted from 31-33)
COX – Cyclooxygenase, LOX: Lipoxygenase, TXA2: Thromboxane A2 (platelet aggregator, vasoconstrictor), PGI2: Prostaglandin I2 (vasodilator, antiaggregator), PGE2: Prostaglandin E2 
(Immunosuppresor)
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Table 2: Characteristics of commercially available intravenous lipid emulsions used in reported randomised controlled trials (2, 28, 29, 32, 42, 
43).
Composition
Abbreviation
Intralipid 
20%
SO
Lipofundin 
20%
MCT/LCT
ClinOleic 20%
OO/SO
SMOFlipid 
20%
SMOF
Omegaven 10%
FO
Not available in SA
Lipoplus 20%
MCT/LCT/FO
Not available in SA
Oil source %
Soy bean
MCT
Olive
Fish
100
0
0
0
50
50
0
0
20
0
80
0
30
30
25
15
0
0
0
100
40
50
0
10
% Fatty acids
Linoleic 
Arachidonic 
α-Linolenic 
EPA 
DHA
53
0.1
8
0
0
50
0.2
7
0
0
18.7
0.5
2.3
0
0
21.4
1.0
2.5
4.7
4.4
4.4
2.1
1.8
19.2
12.1
25.7
NA
3.4
3.7
2.5
ω6 – ω3 ratio 7:1 7:1 9:1 2.5:1 1:8 2.7:1
Phytosterols (mg/l) 348 ± 33 NA 327 ± 8 47.6 0 NA
Phytosterols (mg/l) (44) 439 ± 5.7 278 ± 5.09 274 ± 2.6 207 NA NA
α-tocopherol (mg/l) 38 85 ± 20 32 or 180 200 150-296 190 ± 30
Osmolarity (mOsm/L) 260 380 270 380 308-376 NA
Abbreviations: SO: Soybean oil; MCT: Medium Chain Triglycerides; OO: Olive Oil; FO: Fish oil; EPA: Eicosapentaenoic Acid; DHA: Docosahexaenoic acid
Table 3: Clinical Studies in Septic patients
Study Patients Duration Lipid Emulsion Effects
Barbosa (49) 25 septic pts 5 days LCT/MCT/FO vs
MCT/LCT
FO grp: ↑ EPA, IL-6 ↓ significantly, IL-10 ↓ significantly less.
D6: PaO2/FiO2 ratio was significantly higher. 
No difference in days on ventilator, ICU & hospital LOS. 
No difference in laboratory measurements
Sungurtekin (50) 20 sepsis & 20 
SIRS pts
7 Days MCT/LCT + FO vs
MCT/LCT
LCT/MCT grp: ↑ liver steatosis on D7 & D10. 
No difference in AST, ALT, GGT or CRP. 
IL-6 & TNF-α ↑ on D7, IL-1 ↑ on D3, 7 & 10 in sepsis grp. 
IL-10 significantly ↑ on D3 & D7 in SIRS grp.
Serum LDH & TG significantly ↑ on D7 & D10 for SIRS grp 7 
only ↑ on D7 in sepsis grp.
Friesecke (52) 116 ICU pts ≥7 days MCT/LCT+FO vs
MCT/LCT
FO grp: No effect on inflammation (IL-6) & clinical outcome 
(infections, MV, ICU LOS & 28 day mortality)
Hall (53) 60 critically ill pts 
with sepsis
14 days or 
until discharge
FO supplement FO grp: significant ↓ in new organ dysfunction & max CRP.
No significant ↓ in LOS.
Edmunds (54) 451 critically ill 
pts
12 day or 
death
LCT vs MCT/LCT vs OO/
LCT vs FO vs LCT/MCT/
OO/FO
FO or OO grp vs LCT had shorter time to termination of 
MV & shorter time to ICU discharge.
Khor (6) 28 critically ill 
pts with severe 
sepsis
5 days FO vs Saline FO grp: Significant ↓ in APACHE score & PCT on D3, D5 & 
D7. 
No difference in TNF-α, ICU & hospital LOS and mortality.
Mayer (46) 21 Septic pts 5 days LCT vs LCT + FO FO grp: ↓ cytokine secretion. No effect on length of MV & 
mortality.
Mayer (47) 10 Septic pts 10 days LCT vs LCT + FO FO grp: ↑ EPA & DHA over AA. ↑ LTB5. Improved neutrophil 
function. 
No effect on length of MV & mortality.
Heller (48) 661 ICU pts 
Multicentre
≥3 days FO at different doses FO grp at 0.1 – 0.2g/kg showed favourable effects on 
survival, infection rate & LOS. 
↓ Antibiotics at 0.15 - 0.2g/kg.
Grecu (51) 54 pts with 
abdominal sepsis
5 days LCT + FO vs LCT Significant ↓ reoperation rates, ICU and hospital LOS. CRP 
lower in FO group on day 5. 
No difference in mortality.
Grau-Carmona (61) 159 ICU pts ≥ 5days MCT/LCT vs LCT/MCT/
FO
FO grp: Fewer instances of nosocomial infections.
Similar clinical outcomes (mortality, hospital LOS, day on 
MV)
Abbreviations: Pts: patients; MV: Mechanical Ventilation; PCT: procalcitonin; ICU: Intensive Care Unit; EPA: Eicosapentaenoic Acid;  DHA: Docosahexaenoic Acid; AA: Arachidonic Acid; CRP: 
C-reactive protein; FO: Fish Oil; LCT: Long chain Triglyceride; MCT: Medium Chain Triglyceride; OO: Olive Oil; LTB5: Leukotriene B5; AST: Aspartate aminotransferase; ALT:  Alanine amino 
transferase; GGT: Gamma-Glutamyl transferase; IL-6: Interleukin-6; IL-1β: Interleukin-1β;  TNF-α: Tumor-necrosis Factor-alpha; LDH: Lactate dehydrogenase; PaO2/FiO2: partial pressure arterial 
oxygen and fraction of inspired oxygen ratio.
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Table 4: Clinical Studies in post-surgery patients
Study Patients Duration Lipid Emulsion Effects
Antebi  (74) 20 pts undergoing 
major surgery
≥5 days LCT/MCT/OO/FO  vs  LCT LCT grp: significant ↑ in TG, ALT, ALP & GGT  and ↑ in CRP
FO grp:↑ in α-tocopherol & better liver function
Mertes (78) 199 postop
patients
5 days LCT/MCT/OO/FO vs LCT FO grp: no effect on TG & AST, ALT & GGT & clinical outcome 
LCT grp: AST, ALT & ALP levels were above normal range on D6
Piper (86) 44 postop 
patient 
5 days LCT/MCT/OO/FO vs OO/
LCT 
LCT/MCT/OO/FO grp : improved liver function
Berger (87) 20 pts with
AAA surgery
4 days LCT/MCT/FO vs 
MCT/LCT
LCT/MCT/FO grp: no difference on Inflammatory marker & 
clinical outcome
Han (76) 30 post op
Patients
7 days MCT/LCT vs LCT/MCT 
+FO
LCT/MCT grp: had significant ↑ in TG on D4, no difference on D7. 
Trend for ↑ in AST, ALT & bilirubin, not significant. 
LCT/MCT +FO grp: ↓ in IL-1. IL-8, IFN-γ, TNF-α & significant ↓ in 
IL-6.
Wu (88) 40 GI surgery 
patients
5 days LCT/MCT/OO/FO vs
MCT/LCT
MCT/LCT grp: significant ↑ in TG on D2 & D6. 
No difference in other laboratory parameters (LFTs). 
No difference in inflammatory markers.
Tsekos (89) 249 ICU pts
Major 
Abdominal surgery
2 yr 
database
MCT/LCT grp 1
MCT/LCT + FO grp 2
MCT/LCT + FO preop
grp 3
Significant ↓ in mortality in grp 3  vs grp 1.
No. of pts requiring MV lower in grp 3. No difference in ICU LOS. 
Hospital LOS was significantly ↓ in grp 3.
Zhu (90) 76 pancreatico-
duodenectomy 
patients
5 days MCT/LCT vs MCT/LCT 
+ FO
FO grp: less ↓ in total protein & prealbumin. 
Significant ↓ in ALT, AST & LDH on D6.
Significant ↓ in infectious complications & post op hospital LOS. 
No difference in mortality.
Badia-Tahull 
(91)
27 elective GI
Surgery patients
5 days FO + OO/LCT vs
OO/LCT
FO grp: Significant ↓ in infections. 
CRP, prealbumin & leukocytes not significantly different. 
No difference in safety parameters.
Wang (80) 64 GI surgery 
patients
5 days MCT/LCT vs 
MCT/LCT/FO
No difference in infectious complications.
FO grp: ↓ in total bilirubin vs ↑ in control grp. 
No difference in CRP, IL-1, IL-8, IL-10.
Significant ↑in LTB5:LTB4 ratio & ↓ in IL-6, TNF-α & NFĸB. 
No difference in LFTs or TG.
Jiang (77) 206 GI cancer 
surgical patients
7 days LCT vs LCT/FO FO grp: Less infectious complications & significantly ↓ SIRS. 
Hospital LOS significantly ↓
Wei (92) 48 GI Cancer surgery 
patients
6 days LCT vs LCT + FO No significant difference in LFTs & renal function. 
FO grp: Post op WBC, IL-6, IL-1β & TNF-α significantly ↓ 
Rate of complications ↓.
Llop- 
Talaveron (93)
52 PN patients 14-31.8 
days
MCT/LCT or
OO/LCT for 1st wk
FO-LE added 2nd wk
GGT, ALP & total Bilirubin ↑ Significantly in 1st wk. 
After FO added GGT, ALP & ALT ↓.
Grimm (75) 33 major abdominal
Surgical patients
5 days LCT vs
LCT/MCT/OO/FO
TG, phospholipids & total cholesterol similar in both grps.
FO grp: On D6 α-tocopherol significantly ↑. ↓ LOS .
Heller (94) 44 major abdominal 
surgical patients
5 days LCT vs LCT + FO No differences were observed in terms of coagulation & platelet 
function at 0.2g/kg FO.
Heller (95) 661 post-op &
Septic pts
≥ 3 days Different ω-6:ω-3 PUFA
ratio
ω-6:ω-3 PUFA ratio 2:1 ↓ ICU LOS.
No difference in mortality.
Genton (96) 32 post op patients 7-14 days LCT vs LCT/MCT/OO/FO No difference in TG, total cholesterol and liver functions
Ma (97) 99 gastrointestinal 
cancer surgery 
patient
1 day 
before 
& 7 days 
post-op
MCT/LCT/FO vs MCT/
LCT
FO: Improved lipid metabolism.
No effect on metabolic parameters, proinflammatory cytokine 
levels, adverse events and clinical outcomes
Metry (98) 83 post-op ICU 
patients
7 days LCT/MCT/OO/FO vs LCT No significant differences in laboratory profiles of cholesterol, TG 
and liver enzymes.
IL-6 levels were significantly different between 2 group and IL-6 
was significantly lower in FO group on D4 & D7.
Senkal (99) 40 colorectal surgery 
patients
5 days MCT/LCT vs LCT/MCT/
FO
FO: significant increase in EPA and DHA levels. Increase in ω-6:ω- 
3 PUFA ratio.
AA not significantly different in both groups
Abbreviations: AAA: abdominal aortic aneurysm; TG: Triglycerides; LOS: Length of Stay; FO: Fish Oil; LCT: Long chain Triglyceride; MCT: Medium Chain Triglyceride; OO: Olive Oil; MV: Mechanical 
Ventilation; WBC: White Blood count; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-Glutamyl Transferase; IL-6: Interleukin-6; IL-1β: Interleukin-1β; IL-8: 
Interleukin-8; TNF-α: Tumour-necrosis Factor-alpha; IFN-γ: Interferon – gamma; LDH: Lactate dehydrogenase; LFTs: Liver Function Tests; ICU: Intensive Care Unit; grp: group; CRP: C-reactive 
protein; NFĸB: Nuclear factor kappa-light-chain-enhancer of activated B cells; SIRS: Systemic Inflammatory response syndrome; pts: patients; GI: Gastrointestinal; post-op: Post-operative; LTB5: 
Leukotriene B5; LTB4: Leukotriene B4
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